Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | +7.92% | -5.22% | +98.18% |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
04-01 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Business Summary
Number of employees: 73
Managers
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 21/05/19 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 30/09/22 | |
Chief Operating Officer | 42 | 28/02/21 | |
Uli Bialucha
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/21 |
Scott Coleman
PRN | Corporate Officer/Principal | - | 31/05/22 |
Stacey J. Davis
PRN | Corporate Officer/Principal | - | 16/05/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 22/07/20 |
Daniel Curran
BRD | Director/Board Member | 57 | 30/11/20 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 14/09/22 |
Sara Bonstein
BRD | Director/Board Member | 43 | 16/08/21 |
Robert Ross
BRD | Director/Board Member | 50 | 15/06/22 |
René Russo
CEO | Chief Executive Officer | 49 | 21/05/19 |
Christina Rossi
BRD | Director/Board Member | 48 | 31/03/21 |
Yuan Xu
BRD | Director/Board Member | 56 | 03/01/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,479,103 | 23,477,593 ( 68.09 %) | 5,617 ( 0.0163 %) | 68.09 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.18% | 37.57M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XLO Stock
- Company Xilio Therapeutics, Inc.